ZA200806457B - Use of 4-imidazole derivatives for CNS disorders - Google Patents

Use of 4-imidazole derivatives for CNS disorders

Info

Publication number
ZA200806457B
ZA200806457B ZA200806457A ZA200806457A ZA200806457B ZA 200806457 B ZA200806457 B ZA 200806457B ZA 200806457 A ZA200806457 A ZA 200806457A ZA 200806457 A ZA200806457 A ZA 200806457A ZA 200806457 B ZA200806457 B ZA 200806457B
Authority
ZA
South Africa
Prior art keywords
imidazole derivatives
cns disorders
cns
disorders
imidazole
Prior art date
Application number
ZA200806457A
Other languages
English (en)
Inventor
Galley Guido
Groebke Zbinden Katrin
Hoener Marius
Norcross Roger
Stalder Henri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200806457B publication Critical patent/ZA200806457B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200806457A 2006-01-27 2008-07-24 Use of 4-imidazole derivatives for CNS disorders ZA200806457B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06100938 2006-01-27

Publications (1)

Publication Number Publication Date
ZA200806457B true ZA200806457B (en) 2009-11-25

Family

ID=38051581

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200806457A ZA200806457B (en) 2006-01-27 2008-07-24 Use of 4-imidazole derivatives for CNS disorders

Country Status (18)

Country Link
US (1) US8158668B2 (fr)
EP (1) EP1981880B1 (fr)
JP (1) JP2009524616A (fr)
KR (1) KR101079914B1 (fr)
CN (1) CN101374832B (fr)
AR (1) AR059206A1 (fr)
AT (1) ATE458732T1 (fr)
AU (1) AU2007209380B2 (fr)
BR (1) BRPI0706759A2 (fr)
CA (1) CA2637308C (fr)
DE (1) DE602007004949D1 (fr)
ES (1) ES2338716T3 (fr)
IL (1) IL192885A0 (fr)
NO (1) NO20083356L (fr)
RU (1) RU2008130448A (fr)
TW (1) TW200738645A (fr)
WO (1) WO2007085556A2 (fr)
ZA (1) ZA200806457B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1981497A2 (fr) 2006-01-27 2008-10-22 F.Hoffmann-La Roche Ag Utilisation de 2-imidazole substitue de derives d'imidazoline
BRPI0717939A2 (pt) 2006-10-19 2013-12-03 Hoffmann La Roche Aminometil-4-imidazóis
UA98951C2 (ru) 2007-02-02 2012-07-10 Ф. Хоффманн-Ля Рош Аг 2-аминооксазолины и лекарственное средство, которое их содержит
EP2125749A2 (fr) 2007-02-13 2009-12-02 Schering Corporation Agonistes des récepteurs adrénergiques alpha2c fonctionnellement sélectifs
MX2009008776A (es) * 2007-02-13 2009-08-25 Schering Corp Agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos.
CL2008000429A1 (es) 2007-02-13 2008-08-18 Schering Corp Compuestos derivados de heterociclos condensados; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar afecciones asociadas con los receptores alfa2c adrenergicos, tales como congestion asociada a rinitis, polipos, resfrio
WO2009003867A1 (fr) * 2007-07-03 2009-01-08 F. Hoffmann-La Roche Ag 4-imidazolines et leur utilisation comme antidépresseurs
US7902247B2 (en) 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
JP5453312B2 (ja) * 2008-01-18 2014-03-26 アラーガン インコーポレイテッド アルファ２ｂおよび／またはアルファ２ｃアドレナリンレセプターのサブタイプ選択性モジュレーターである置換アリール‐（イミダゾール）‐メチル）‐フェニル化合物
JP5547187B2 (ja) * 2008-07-24 2014-07-09 エフ．ホフマン−ラ ロシュ アーゲー ４，５−ジヒドロ−オキサゾール−２−イル誘導体
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
WO2011028621A1 (fr) * 2009-08-26 2011-03-10 Allergan, Inc. Procédé de traitement de troubles compulsifs par les agonistes du récepteur alpha-2b adrénergique
UY32858A (es) 2009-08-31 2011-03-31 Abbott Healthcare Products Bv Derivados de (tio)morfolina como moduladores de sip
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
TWI543984B (zh) 2010-07-09 2016-08-01 艾伯維公司 作為s1p調節劑的螺-哌啶衍生物
AR090557A1 (es) 2012-04-02 2014-11-19 Orion Corp DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
EA028033B1 (ru) 2013-03-14 2017-09-29 Новартис Аг 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантного idh
ES2856189T3 (es) * 2013-10-07 2021-09-27 Teikoku Pharma Usa Inc Métodos y composiciones para el tratamiento del trastorno de hiperactividad por déficit de atención, ansiedad e insomnio utilizando composiciones transdérmicas de dexmedetomidina
CA2924231C (fr) 2013-10-07 2018-04-03 Teikoku Pharma Usa, Inc. Dispositifs d'administration transdermique de dexmedetomidine et leurs methodes d'utilisation
WO2015054061A1 (fr) 2013-10-07 2015-04-16 Teikoku Pharma Usa, Inc. Procédés et compositions pour l'administration transdermique d'une quantité non sédative de dexmédétomidine
CN103664788B (zh) * 2013-12-04 2015-11-25 湖北生物医药产业技术研究院有限公司 制备美托咪啶的方法
WO2017134053A1 (fr) 2016-02-04 2017-08-10 Chiesi Farmaceutici S.P.A. Dérivés de pyrazole à utiliser en tant qu'inhibiteurs de phosphoinositide 3-kinases
PT3430010T (pt) 2016-03-17 2020-09-10 Hoffmann La Roche Derivado de 5-etiol-4-metil-pirazol-3-carboxamida com atividade de agonista de taar
CN105884691B (zh) * 2016-06-02 2017-08-25 江苏恒瑞医药股份有限公司 一种制备右美托咪定及其中间体的方法
JP7343170B2 (ja) * 2017-05-12 2023-09-12 ボード オブ トラスティーズ オブ ザ サザン イリノイ ユニバーシティ オン ビハーフ オブ サザン イリノイ ユニバーシティ エドワーズビル ３，４，５－三置換－１，２，４－トリアゾールおよび３，４，５－三置換－３－チオ－１，２，４－トリアゾール、ならびにそれらの使用
CN107879979B (zh) * 2017-10-27 2020-08-25 广东莱佛士制药技术有限公司 一种右美托咪定的制备方法
TW202132311A (zh) 2019-10-31 2021-09-01 美商Ｅ 斯蓋普生物股份有限公司 S1p受體調節劑之固體形式

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7312245A (nl) * 1973-09-06 1975-03-10 Stamicarbon Werkwijze voor het bereiden van alphamethylstyreen bevattende blokcopolymeren.
AU518569B2 (en) * 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
GB2101114B (en) * 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
JPH0733333B2 (ja) * 1986-12-12 1995-04-12 三井石油化学工業株式会社 脳機能改善薬
GB2215206B (en) * 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
FI894911A0 (fi) * 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
GB2256135B (en) 1991-05-31 1995-01-18 Orion Yhtymae Oy Transdermal administration of 4-substituted imidazoles
GB9521680D0 (en) 1995-10-23 1996-01-03 Orion Yhtymo Oy New use of imidazole derivatives
BR9813381A (pt) * 1997-12-04 2000-10-03 Allergan Sales Inc "derivados de imidazol substituìdo possuindo atividade semelhante a agonista em receptores adrenérgicos alfa 2b ou 2b/2c"
JP4546589B2 (ja) * 1998-04-23 2010-09-15 武田薬品工業株式会社 ナフタレン誘導体
AU3534699A (en) * 1998-04-23 1999-11-08 Takeda Chemical Industries Ltd. Naphthalene derivatives, their production and use
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
JP4520012B2 (ja) * 1999-10-22 2010-08-04 武田薬品工業株式会社 １−置換−１−（１ｈ−イミダゾール−４−イル）メタノール類
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
BRPI0411867A (pt) * 2003-07-09 2006-08-08 Hoffmann La Roche tiofenilaminoimidazolinas
CA2538445A1 (fr) * 2003-09-12 2005-04-21 Allergan, Inc. Procedes et compositions destines au traitement de la douleur et d'autres etats a mediation adrenergique alpha-2
EP1797043A1 (fr) * 2004-09-24 2007-06-20 Allergan, Inc. 4-(phenylmethyl et substitues de phenylmethyls)-imidazole-2-thiones agissant comme agonistes adrenergiques alpha2 specifiques

Also Published As

Publication number Publication date
AU2007209380B2 (en) 2011-12-08
CN101374832B (zh) 2013-03-06
EP1981880B1 (fr) 2010-02-24
IL192885A0 (en) 2009-02-11
US8158668B2 (en) 2012-04-17
WO2007085556A3 (fr) 2007-10-04
AR059206A1 (es) 2008-03-19
WO2007085556A2 (fr) 2007-08-02
KR101079914B1 (ko) 2011-11-04
CA2637308A1 (fr) 2007-08-02
ATE458732T1 (de) 2010-03-15
TW200738645A (en) 2007-10-16
BRPI0706759A2 (pt) 2011-04-05
DE602007004949D1 (de) 2010-04-08
EP1981880A2 (fr) 2008-10-22
CA2637308C (fr) 2014-02-25
KR20080088658A (ko) 2008-10-02
ES2338716T3 (es) 2010-05-11
CN101374832A (zh) 2009-02-25
RU2008130448A (ru) 2010-03-10
US20070197622A1 (en) 2007-08-23
NO20083356L (no) 2008-10-21
AU2007209380A1 (en) 2007-08-02
JP2009524616A (ja) 2009-07-02

Similar Documents

Publication Publication Date Title
IL192885A0 (en) Use of 4-imidazole derivatives for cns disorders
IL192690A0 (en) Hydantoin derivatives for the treatment of inflammatory disorders
AU2008281877A8 (en) The use of benzamide derivatives for the treatment of CNS disorders
ZA200806074B (en) Compounds for the treatment of inflammatory disorders
IL241791A0 (en) Historical use of 3,1-diphenylprop-2-en-1-one for the treatment of liver disorders
EP2010187A4 (fr) Composés pour le traitement de maladies et de troubles
EP1901733A4 (fr) Utilisation d'huperzine pour des pathologies
ZA200801888B (en) Derivatives of 4-piperazin-1-1-YL-4-benzo [B] thiophene suitable for the treatment of CNS disorders
IL180736A0 (en) Hydantoin derivatives for the treatment of inflammatory disorders
IL194114A0 (en) Treatment of cns conditions
IL198847A0 (en) New process for the preparation of 2-imino-thiazolidin-4-one derivatives
IL196202A0 (en) Indazole derivatives for the treatment of hsp90-induced diseases
EP2139475A4 (fr) Utilisation d'inhibiteurs pde7 dans le traitement des troubles du
ZA200806455B (en) Use of 2-imidazoles for the treatment of CNS disorders
IL197695A0 (en) 3-amino-pyridine derivatives for the treatment of metabolic disorders
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
EP2099444A4 (fr) Utilisation de dérivés de la d-sérine pour le traitement de troubles de l'anxiété
HK1129112A1 (en) 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders
IL194873A0 (en) Methods for reducing 7/9-nitrotetracycline derivatives
GB0604772D0 (en) Use of substituted amine compounds for the treatment of food related disorders
GB0616452D0 (en) Novel therapy for joint disorders
IL194261A0 (en) S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
GB0618705D0 (en) Treatment of joint disorders
IL197485A0 (en) Use of vitamin d compounds for the prevention of adhesions
PL380796A1 (pl) Środek do flotacji węgla